Dibromdulcitol containing chemotherapeutic regimen in the treatment of childhood Hodgkin's disease.
Dibromdulcitol containing modified MOPP chemotherapeutic regimen plus radiotherapy were used in 58 children with Stage I-IV Hodgkin's disease diagnosed between 1975 and 1985 in Hungary. A remission rate of 93.1% and a 5-year relapse-free survival of 89% was observed. Some latent hyperthyreoidism as late effect of the therapy, no growth disturbances and no adverse gonadal effects were seen until now.
Schuler
D
D
2nd Department of Pediatrics, Semmelweis University of Medicine, Budapest, Hungary.
Kardos
G
G
Révész
T
T
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols; D002648:Child; D002675:Child, Preschool; D005260:Female; D006689:Hodgkin Disease / Q000000981:diagnostic imaging / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008466:Mechlorethamine / Q000627:therapeutic use; D008936:Mitolactol / Q000008:administration & dosage* / Q000009:adverse effects; D011241:Prednisone / Q000627:therapeutic use; D011344:Procarbazine / Q000627:therapeutic use; D011859:Radiography; D014750:Vincristine / Q000627:therapeutic use
D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D008936:Mitolactol; D011241:Prednisone